GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » EV-to-EBITDA

Renalytix (LSE:RENX) EV-to-EBITDA : -1.71 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Renalytix EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Renalytix's enterprise value is £31.38 Mil. Renalytix's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was £-18.38 Mil. Therefore, Renalytix's EV-to-EBITDA for today is -1.71.

The historical rank and industry rank for Renalytix's EV-to-EBITDA or its related term are showing as below:

LSE:RENX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -48.13   Med: -1.64   Max: -0.36
Current: -1.71

During the past 7 years, the highest EV-to-EBITDA of Renalytix was -0.36. The lowest was -48.13. And the median was -1.64.

LSE:RENX's EV-to-EBITDA is ranked worse than
100% of 481 companies
in the Healthcare Providers & Services industry
Industry Median: 12.24 vs LSE:RENX: -1.71

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-11), Renalytix's stock price is £0.085. Renalytix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was £-0.196. Therefore, Renalytix's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Renalytix EV-to-EBITDA Historical Data

The historical data trend for Renalytix's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix EV-to-EBITDA Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial -37.14 -30.26 -1.28 -2.89 -0.89

Renalytix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.77 -0.56 -1.69 -0.89 -1.02

Competitive Comparison of Renalytix's EV-to-EBITDA

For the Health Information Services subindustry, Renalytix's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Renalytix's EV-to-EBITDA falls into.



Renalytix EV-to-EBITDA Calculation

Renalytix's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=31.383/-18.381
=-1.71

Renalytix's current Enterprise Value is £31.38 Mil.
Renalytix's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-18.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (LSE:RENX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Renalytix's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.085/-0.196
=At Loss

Renalytix's share price for today is £0.085.
Renalytix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.196.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Renalytix EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Renalytix's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix Business Description

Traded in Other Exchanges
Address
2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix Headlines

From GuruFocus

Investing in Information

By Vanina Egea Vanina Egea 03-06-2014

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe 08-29-2013

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex 12-14-2012